

## Diabetes Management Committee meeting

**Date:** 17/07/2017

**Location:** London

**Minutes:** Final

<b>Committee members present:</b>	
Steve Pilling (Chair) (SP)	Section 1- 6
Andrew Barron (Topic Expert) (AB)	Section 1- 6
Simon Corbett (Condition Specific) (SC)	Section 1- 6
Jim Gray (Core Member) (JG)	Section 1- 6
Jo Josh (Core Member) (JJ)	Section 1- 6
Bernard Khoo (Condition Specific) (BK)	Section 1- 6
David Liggins (Condition Specific) (DL)	Section 1- 6
Jean MacLeod (Condition Specific) (JM)	Section 1- 6
Grace Marsden (GM) (Core Member) (GM)	Section 1- 6
Julian Treadwell (Core Member) (JT)	Section 1- 6

<b>In attendance:</b>		
Omnia Abdulrazeg (OA)	Technical Analyst – NICE	Section 1- 6
Chris Gibbons (CG)	Health Economist – NICE	Section 1- 6
Andy Hutchinson (AH)	Technical Adviser – NICE	Section 1- 6
Jane Lynn (JL)	Resource Impact Lead – NICE	Section 1- 6
Yolanda Martinez (YM)	Technical Analyst – NICE	Section 1- 6
Adam O’Keefe (AO)	Project Manager – NICE	Section 1- 6
Joshua Pink (JP)	Technical Adviser – NICE	Section 1- 6
Nick Staples (NS)	Guideline Commissioning Manager – NICE	Section 1- 6

<b>Observers:</b>		
Sarah Boyce	Technical Analyst – NICE	Section 1- 6
Verena Wolfram	Technical Analyst – NICE	Section 1- 6

## Diabetes Management: Minutes

### Apologies:

Parveen Ali (Core Member)

Ivan Benett (Condition Specific)

Krishnarajah Nirantharakumar (Topic Expert)

Dianna Oxley (Condition Specific)

### 1. Welcome

The Chair welcomed the Committee members and attendees to the first meeting on Diabetes Management.

The meeting was opened to the public. The Committee and NICE team introduced themselves. The Chair informed the Committee that apologies had been received which are noted above.

The Chair welcomed the members of the public to the meeting. The members of the public had been briefed already, both verbally and in writing by the NICE team, and the Chair reminded them of the protocol for members of the public, whose role is to observe (they should not speak or ask questions). No filming or recording of the meeting is permitted. The Chair reminded all present that the Committee is independent and advisory, that its decisions and recommendations to NICE do not represent final NICE guidance, and that they may be changed as a result of public consultation.

The Chair outlined the objectives of the meeting:

- To review questions 1 and 2a and make recommendations if appropriate to do so;
- To consider the health economic model

Committee members had previously been asked to complete a Declarations of Interest form. The Chair asked the Committee members and the NICE team to declare if they have any additional conflicts of interest, or conflicts relating to today's meeting agenda. The following new interest was declared:

Name	Job title, organisation	Declarations of Interest, date declared	Classification of interest	Decision taken
<b>Topic expert members</b>				

## Diabetes Management: Minutes

Jean MacLeod	Consultant Physician in Diabetes and General Medicine	Attended pharmacy supported training for Health Visitors and District Nurses which included all medicines being discussed at this meeting.  <b>Declared – 17/07/2017</b>	Personal Non-financial Specific	Declare and Participate
--------------	---	--	---------------------------------	-------------------------

DL noted minor amendments to previous declarations conflicts. The DOI register will be updated to reflect these.

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent attendees from fully participating in the meeting.

### **2. Review question 1: In adults with Type 2 diabetes, what is the clinical effectiveness of SGLT-2 inhibitors on cardiovascular outcomes? (document 5)**

YM reminded the Committee that this question was briefly discussed at the previous meeting where the Committee provided clarification on a number of queries from the NICE team. YM then presented the clinical evidence supporting Review Question 1 for the Committee's consideration. The Committee discussed the evidence and agreed the evidence statements drafted by the NICE team.

### **3. Review question 2a: In adults with Type 2 diabetes, what is the clinical effectiveness of GLP1 mimetics on cardiovascular outcomes?**

OA recapped the evidence presented at the previous meeting supporting Review Question 2a and then presented details of a recently published trial for the Committee's consideration. The Committee discussed the available evidence and how the new study impacts on the current recommendations.

### **4. Health Economics**

CG presented the health economic evidence supporting Review Question 1 for the Committee's consideration, highlighted difficulties with the model and outlined options for the way forward. The Committee discussed the economic modelling considerations relating to the review question and options on how to proceed. The Committee agreed that in order to update the health economic model, a fuller update of the guideline would be required.

### **5. Discussion and recommendations (CLOSED SESSION)**

The NICE team outlined the equalities considerations the Committee need to reflect upon when drafting recommendations, which were then discussed by the

## Diabetes Management: Minutes

Committee.

The Committee discussed the evidence presented and their own clinical and lay experiences and drafted two recommendations and two research recommendations covering Review Questions 1 and 2a<sup>1</sup>.

### **6. Next steps and AOB**

AO advised the Committee on the next phase key dates for the update. The Chair summarised the day and thanked the Committee for their contribution to the meeting.

**Date of next meeting:** 13 October 2017

**Location of next meeting:** NICE London Office

---

<sup>1</sup> Following this meeting, the NICE development and quality assurance teams discussed the draft recommendations in the context of the evidence. NICE agreed that there was insufficient evidence to make definitive recommendations for practice as trials have only reported on some of the drugs in the SGLT-2 and GLP-1 classes, with trials of others still ongoing. NICE agreed to suspend the guideline, pending further trial data emerging.